Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment[1][2].
Tubulin polymerization-IN-42 (compound 10j), an indole-substituted furanone, is an inhibitor of tubulin polymerization with anti-cancer activity[1].
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2].
BNC105 is a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.IC50 value: Target:BNC105 exhibited excellent potency against a panel of different cancer cell lines with IC50 <1 nM for DU145, Calu-6, MDA-MB-231 etc. The selectivity observed for BNC105 against activated over quiescent HUVECs was also observed in human aortic arterial endothelial cells (HAAECs). BNC105 also exhibited good potency toward the cisplatin resistant cell line A2780cis.